Avita Medical Stock Earnings Reports

Key points for investors: Q1 revenue $19.3M, up 4% YoY and ~10% sequentially — the highest quarterly revenue in the past year. Management says the business is moving from stabilization into execution, with improvements driven by RECELL utilization normalization (all 7 Medicare Administrative Contractors have published payment rates), early commercial traction for Cohealyx, and developing adoption for PermeaDerm. Interim Cohealyx-I data showed materially faster time to graft readiness (median ~11 days, ~20 days improvement vs. benchmark) and investigator satisfaction; full dataset expected later this year. BARDA awarded a long-term agreement that provides modest recurring readiness revenue (guaranteed ~ $3.9M over 10 years) and reinforces government confidence in RECELL for mass-casualty preparedness. Gross margin was 81.7% (decline vs. prior year due to product mix and inventory reserves), RECELL gross margin ~85%. Operating expenses fell 11% YoY to $24.5M due to cost optimization; net loss improved to $10.6M. Cash and marketable securities ended Q1 at ~$14.3M; management expects significantly lower cash burn in Q2 due to seasonal timing and improved collections. Company reaffirmed full-year 2026 revenue guidance of $80M–$85M. Management highlights a shift to more frequent, smaller, procedure-driven orders, improved predictability, and growing clinical engagement following the American Burn Association meeting.